University Research Opens Door to U.S. Market for UK Chemotherapy Scalp Cooling Firm - European Medical Journal

University Research Opens Door to U.S. Market for UK Chemotherapy Scalp Cooling Firm

3 Mins

University of Huddersfield researchers’ breakthroughs on the Paxman Scalp Cooling System has led to the UK company receiving the go-ahead to enter the American market.

Huddersfield, UK, 10 May, 2017 – A pioneering UK company that produces technology designed to reduce hair loss during cancer treatment has been given official clearance to enter the huge U.S. healthcare market.  The firm has had a highly fruitful research partnership with the University of Huddersfield and this will continue, with the aim of making the devices even more effective.

Paxman Coolers Ltd, based in Huddersfield, has developed the Paxman Scalp Cooling System, proven to reduce traumatic hair loss in at least half of women who undergo chemotherapy for breast cancer.  The technology is already well established in the UK and other parts of the world, with more than 2,500 systems currently installed in hospitals and treatment centres.

Now, after exhaustive trials, the U.S. Food and Drug Administration (FDA) has cleared the company to market the product in the USA, and there are immediate plans to install 250 Paxman Scalp Cooling Systems across the country.

The Paxman firm has worked closely with the University of Huddersfield for five years.  In its School of Art, Design and Architecture, Dr Ertu Unver has worked on the design of the cooling caps.  And in the School of Applied Sciences, Dr Nikolaos Georgopoulos, a specialist in cancer research, has worked with colleagues and PhD students to gain an understanding of the biological science behind scalp cooling.

The research has led to published articles, and Dr Georgopoulos, Dr Andrew Collett and their team are collaborating with Paxman in applying for a patent that will cover a novel process leading to major gains in the success rate of scalp cooling.

Also, Paxman are now supporting a new 12-month research project with Dr Georgopoulos in the School of Applied Sciences at the University.

“The company’s philosophy is to aim for zero hair loss.  They are funding this work with us to help them achieve that,” said Dr Georgopoulos.  “We can do this because we have understood the biological mechanisms by which cooling protects the hair cells.”

This understanding was the result laboratory research, including work carried out by Dr Georgopoulos’s doctoral student Wafaa Al-Tameemi and Dr Chris Dunnill, currently a Research Fellow in Dr Georgopoulos’s research group and co-supervisor of the 12-month research project.

The Paxman Cooling System originated when mother-of-four Sue Paxman experienced chemotherapy-induced hair loss.  In response, a company was formed to develop technology that would spare others the trauma.  Sue’s son Richard Paxman is its CEO.

“Like my mum, many people find hair loss to be extremely traumatic,” he said.  “It is estimated that eight per cent of patients actually refuse chemotherapy because they do not want to lose their hair.  We have been determined to change this.”

As part of the FDA clearance process in the USA, the Paxman device was used in the first-ever randomised clinical trial to evaluate modern scalp cooling, involving 186 women across New Jersey, New York, Texas, and Ohio.  It was discovered that the cooling cap preserved hair in more than 50 per cent of the women who used it.

Lead researcher Dr Julie Nangia, who is Assistant Professor of Medicine at Baylor College of Medicine, Houston, Texas, USA said: “The Paxman Hair Loss Prevention System is a safe and effective method for reducing hair loss in women being treated with chemotherapy for breast cancer.”

“Hopefully in five years from now, we will consider scalp cooling part of routine practice.”

Richard Paxman added: “The USA is the largest healthcare market in the world with over 1.6 million diagnoses of cancer each year.  We have spent six years conducting a comprehensive multi-centre randomised clinical trial to ensure that our data is as robust as possible.”

The University of Huddersfield- Inspiring Tomorrow’s Professionals
The University of Huddersfield is an inspiring, innovative provider of higher education of international renown.  It has a national reputation in enterprise and innovation and has been the recipient of the Times Higher Education’s University of the Year Award and Entrepreneurial University of the Year as well as a Queen’s Awards for Enterprise.  In the 2015, the University was recognised with 5 star status by international ratings organisation QS Stars for teaching, internationalisation, employability and for facilities and access.

The University annually welcomes 22,000 students to a range of undergraduate and postgraduate programmes across subjects covering…

…the sciences, engineering and IT

…health, education and the social sciences

…business, management, law and accountancy

…architecture, design, humanities and the arts.

The University of Huddersfield’s researchers are dedicated to solving the problems and answering the questions posed by industry, science and society as a whole.  Our pioneering research is showcased by internationally-recognised centres of excellence, strategic industry relationships and a commitment to providing state-of-the-art facilities and equipment.

The Chancellor of the University is His Royal Highness The Duke of York, KG, and the Vice-Chancellor is Professor Bob Cryan CBE.

Media Contact
Jayne Amos
Email: [email protected]
Tel: 01484 472982

PR Manager
John Ramsdin
Email: [email protected]
Tel: 01484 472693

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally